Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/vb-exoJeCoY   Novavax has submitted its long-awaited application for an Emergency Use Authorization to the FDA.  This product that combines purified CoVid spike protein with nanoparticles has the distinct advantage that it only requires refrigeration and storage at temperatures between 36 and 46 degrees Fahrenheit.   As now reported in the New England Journal of Medicine, 29,949 adults in the US and Mexico were randomized in a Phase 3 trial so that twice as many received 2 doses of the vaccine (5 ug of protein antigen and 50 ug of the nanoparticle + Matrix-M adjuvant) 3 weeks apart as received the control placebo vaccination containing no spike protein.   The study data showed that Novavax CoVid was 90% effective at preventing any infection and 100% effective at preventing moderate to severe infection.  Reactions to the vaccine were mild to moderate and transient though more notable after the second than after the first dose.   The catch-22 here is that this vaccine was tested dur